Induction death rate

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%

Pediatric APL patients with FLT3 mutations who received ATRA-based induction therapy had a dramatically higher induction death rate (30%, 7/23) compared to FLT3 wild-type patients (3%, 1/35), with dea

Effect: decline; 30% vs 3%